EP3624810A4 - Nano-aktivierte immuntherapie bei krebserkrankungen - Google Patents
Nano-aktivierte immuntherapie bei krebserkrankungen Download PDFInfo
- Publication number
- EP3624810A4 EP3624810A4 EP18803111.6A EP18803111A EP3624810A4 EP 3624810 A4 EP3624810 A4 EP 3624810A4 EP 18803111 A EP18803111 A EP 18803111A EP 3624810 A4 EP3624810 A4 EP 3624810A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunotherapy
- nano
- cancer
- enabled
- enabled immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Ceramic Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507996P | 2017-05-18 | 2017-05-18 | |
US201862614325P | 2018-01-05 | 2018-01-05 | |
PCT/US2018/033265 WO2018213631A1 (en) | 2017-05-18 | 2018-05-17 | Nano-enabled immunotherapy in cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3624810A1 EP3624810A1 (de) | 2020-03-25 |
EP3624810A4 true EP3624810A4 (de) | 2021-02-17 |
Family
ID=64274728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18803111.6A Pending EP3624810A4 (de) | 2017-05-18 | 2018-05-17 | Nano-aktivierte immuntherapie bei krebserkrankungen |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3624810A4 (de) |
AU (1) | AU2018269742B2 (de) |
CA (1) | CA3063932A1 (de) |
WO (1) | WO2018213631A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
JP7138864B2 (ja) | 2016-02-06 | 2022-09-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫を再構成するための造血ニッチの再現 |
CN115404196A (zh) | 2016-07-13 | 2022-11-29 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
WO2020072366A1 (en) * | 2018-10-01 | 2020-04-09 | The Regents Of The University Of California | Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy |
CN113905764B (zh) * | 2019-05-30 | 2024-06-11 | 伊利诺伊大学董事会 | 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法 |
CN110585131A (zh) * | 2019-09-20 | 2019-12-20 | 宁夏医科大学 | 共载化疗药物的1-甲基色氨酸免疫前药胶束、制备方法及其应用 |
WO2021061837A1 (en) * | 2019-09-23 | 2021-04-01 | President And Fellows Of Harvard College | Biomaterial-based antigen free vaccine and the use thereof |
WO2021076630A1 (en) * | 2019-10-14 | 2021-04-22 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
WO2021096542A1 (en) | 2019-11-12 | 2021-05-20 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof |
CN111333653A (zh) * | 2019-12-16 | 2020-06-26 | 山东大学 | 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用 |
EP4076445A1 (de) | 2019-12-20 | 2022-10-26 | Nammi Therapeutics, Inc. | Formulierte und/oder co-formulierte liposomenzusammensetzungen mit toll-like-rezeptoren(tlr)-agonist-prodrugs zur behandlung von krebs und verfahren dafür |
CN111012919B (zh) * | 2019-12-23 | 2021-06-01 | 山东大学 | 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用 |
KR102491260B1 (ko) * | 2019-12-26 | 2023-01-27 | 연세대학교 산학협력단 | 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물 |
JP2023514324A (ja) | 2020-02-19 | 2023-04-05 | ナミ セラピューティクス, インコーポレイテッド | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
CN111330004B (zh) * | 2020-03-04 | 2023-02-10 | 中国人民解放军军事科学院军事医学研究院 | 二硫化钼纳米片层在制备树突状细胞功能促进剂中的应用 |
AU2021266721A1 (en) * | 2020-05-04 | 2022-12-08 | Drugcendr Australia Pty Ltd. | Methods for treating pancreatic cancer and other solid tumors |
CN115803060A (zh) * | 2020-07-10 | 2023-03-14 | (株) 娜迪安生物公司 | 包含作为活性成分的萘醌基化合物和免疫检查点抑制剂的用于预防或治疗癌症的药物组合物 |
US20230338363A1 (en) * | 2020-08-07 | 2023-10-26 | The Regents Of The University Of California | Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-pd-1 |
WO2022055542A1 (en) | 2020-09-10 | 2022-03-17 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
JP2023551771A (ja) * | 2020-12-01 | 2023-12-13 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 免疫調節剤を用いて免疫療法に対するがんの感受性を高める方法 |
US20220401451A1 (en) | 2021-03-18 | 2022-12-22 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereof |
CN113332450B (zh) * | 2021-05-11 | 2023-08-04 | 铜仁学院 | 一种眼部给药递释系统氧化锌纳米粒的制备方法及其使用方法和应用 |
CN113353939B (zh) * | 2021-05-25 | 2023-09-08 | 中国科学院上海硅酸盐研究所 | 一种带隙可调、降解性可控的二维氢硅烯纳米材料及其制备方法和应用 |
CN114890385B (zh) * | 2021-07-01 | 2023-09-08 | 中国科学院上海硅酸盐研究所 | 一种高效抗氧化二维氢锗烯纳米片及其制备方法和应用 |
AU2022393147A1 (en) | 2021-11-18 | 2024-05-23 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated nanocarriers compositions containing immunogenic cell death (icd) inducing prodrugs useful in the treatment of cancer and methods thereof |
WO2023172300A1 (en) * | 2022-03-10 | 2023-09-14 | The Regents Of The University Of California | A drug nanocarrier system to deliver a combination of tlr agonists and/or a lipoxin plus immunogenic cell death inducing chemotherapeutic agents for cancer immunotherapy |
US20240108732A1 (en) | 2022-03-10 | 2024-04-04 | Nammi Therapeutics, Inc. | Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof |
WO2023183872A1 (en) * | 2022-03-23 | 2023-09-28 | You First Services, Inc. | Delmopinol and delmopinol salt containing nanoparticles and uses thereof |
CN114748414B (zh) * | 2022-04-20 | 2024-05-31 | 中国医学科学院生物医学工程研究所 | 一种共负载化疗药和纳米粒的海藻酸钠水凝胶复合体系及其制备方法和应用 |
CN116492452A (zh) * | 2023-04-17 | 2023-07-28 | 同济大学 | Syrosingopine/LOD共负载纳米酶、其制备方法和应用 |
CN116327979B (zh) * | 2023-05-25 | 2023-08-01 | 西南石油大学 | 一种过渡金属基介孔纳米催化药物、制备方法及用途 |
CN117860778A (zh) * | 2024-01-02 | 2024-04-12 | 中国人民解放军总医院第一医学中心 | 一种铁单原子担载氧化石墨烯药物、制备方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
WO2017023667A1 (en) * | 2015-07-31 | 2017-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immunostimulatory nanocarrier |
WO2018140826A1 (en) * | 2017-01-27 | 2018-08-02 | The Methodist Hospital | Core/shell structure platform for immunotherapy |
WO2019173391A1 (en) * | 2018-03-06 | 2019-09-12 | Rita Elena Serda | A high capacity platform for immunogenic cancer cell death |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10828255B2 (en) * | 2013-03-05 | 2020-11-10 | The Regents Of The University Of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
WO2017201528A1 (en) * | 2016-05-20 | 2017-11-23 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
-
2018
- 2018-05-17 WO PCT/US2018/033265 patent/WO2018213631A1/en unknown
- 2018-05-17 EP EP18803111.6A patent/EP3624810A4/de active Pending
- 2018-05-17 AU AU2018269742A patent/AU2018269742B2/en active Active
- 2018-05-17 CA CA3063932A patent/CA3063932A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
WO2017023667A1 (en) * | 2015-07-31 | 2017-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immunostimulatory nanocarrier |
WO2018140826A1 (en) * | 2017-01-27 | 2018-08-02 | The Methodist Hospital | Core/shell structure platform for immunotherapy |
WO2019173391A1 (en) * | 2018-03-06 | 2019-09-12 | Rita Elena Serda | A high capacity platform for immunogenic cancer cell death |
Non-Patent Citations (3)
Title |
---|
ANU PURI ET AL: "Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic", PUBMED CENTRAL (PMC) AUTHOR MANUSCRIPT - HHS PUBLIC ACCESS, 14 June 2010 (2010-06-14), pages 1 - 48, XP055580417, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885142/> [retrieved on 20190412] * |
JING-JING SUN ET AL: "Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier", ACTA PHARMACOLOGICA SINICA, vol. 38, no. 6, 8 May 2017 (2017-05-08), GB, pages 823 - 834, XP055580410, ISSN: 1671-4083, DOI: 10.1038/aps.2017.44 * |
See also references of WO2018213631A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018213631A1 (en) | 2018-11-22 |
CA3063932A1 (en) | 2018-11-12 |
AU2018269742B2 (en) | 2024-01-11 |
EP3624810A1 (de) | 2020-03-25 |
AU2018269742A1 (en) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3624810A4 (de) | Nano-aktivierte immuntherapie bei krebserkrankungen | |
AU2021236446A1 (en) | CRISPR-Cas-related methods, compositions and components for cancer immunotherapy | |
IL261163A (en) | Methods related to crispr-cpf1, compositions and compositions for cancer immunotherapy | |
EP3364949A4 (de) | Krebsimpfstoffe | |
EP3286361A4 (de) | Krebsneoepitope | |
EP3240801A4 (de) | Kombinationstumorimmuntherapie | |
EP3280738A4 (de) | Krebsneoepitope | |
EP3226898A4 (de) | Bromodomäneninhibitor als adjuvans in der immuntherapie von krebs | |
EP3250695A4 (de) | Universelle immunzellen für krebsimmuntherapie | |
EP3160497A4 (de) | Konjugate für immuntherapie | |
EP3247408A4 (de) | Zusammensetzungen und verfahren für die krebsimmuntherapie | |
EP3500262A4 (de) | Zusammensetzungen und verfahren für die krebsimmuntherapie | |
EP3390378A4 (de) | Kleine moleküle gegen krebs | |
EP3703711A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs mit anti-ror1-immuntherapie | |
EP3474854A4 (de) | Krebsbehandlungskombinationen | |
EP3413927A4 (de) | Krebstherapie | |
EP3597061A4 (de) | Büstenhalter | |
EP3292140A4 (de) | Immunotherapeutikum gegen krebs | |
EP3202909A4 (de) | Krebsspezifisches splicing-ribozym und verwendung davon | |
EP3265179A4 (de) | Beta-catenin-inhibitoren in der krebsimmuntherapie | |
EP3638247A4 (de) | Zusammensetzungen und verfahren zur verbesserung einer chemotherapie gegen krebs | |
EP3733175A4 (de) | Therapeutika gegen krebs | |
EP3347098A4 (de) | Abzielung auf mda-5-aktivierung für krebsimmuntherapie | |
EP3310915A4 (de) | Tumorimmuntherapie | |
EP4045054A4 (de) | Nano-aktivierte immuntherapie bei krebserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191119 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031711500 Ipc: A61K0047500000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210118 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/7115 20060101ALI20210112BHEP Ipc: A61K 47/69 20170101ALI20210112BHEP Ipc: A61K 31/7125 20060101ALI20210112BHEP Ipc: A61K 47/50 20170101AFI20210112BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |